In this week’s video, Dr. Brian G.M. Durie defines minimal residual disease (MRD) and explains how MRD-testing can be used for ongoing monitoring.


As it may one day be a guide for assessing treatment outcomes, myeloma patients should familiarize themselves with MRD-testing.

Have a question? Submit it to

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at

Previous Post
Top Five Trends in Myeloma News for 2018
Next Post
What are the prospects for early diagnosis, CRISPR gene-editing, and CAR T-cell therapies in myeloma?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.